European meeting of ISMPP 2021
Collaboration, connectivity and change
24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
Making a difference to our communities across the globe As our employees’ fundraising was affected by the COVID-19 pandemic, our company Charity Team wanted to use the charity budget to maximize our support for hard-pressed charities, while giving our employees the opportunity to give back during lockdown. Therefore, we launched the ‘Make a Difference’ (MAD)…
16–19 November The ISPOR Europe 2020 conference was the society’s first ever virtual meeting. It brought together a vibrant community of experts and thought leaders to help to shape the future of health economics and outcomes research (HEOR). The theme of the 2020 meeting was Improving Health: Establishing Incentives and Sharing Value, and it sought…
Oxford PharmaGenesis attended the Australasian Medical Writers Association (AMWA) special virtual event showcasing the ways in which medical communication has changed in 2020. Oxford PharmaGenesis was proud to sponsor the AMWA 2020 special virtual event, ‘Medical Writing and Communication During the COVID-19 Crisis’, which took place on 19 November, in lieu of what would have…
Earlier this month, six Oxford PharmaGenesis editors attended sessions of the online Chartered Institute of Editing and Proofreading (CIEP) conference. A range of topics were presented, including use of macros in editing, style sheets, digital marketing and inclusive language. Some of the presentations provided essential ‘nuts and bolts’ information, while others took a more in-depth…
The Oxford PharmaGenesis Patient Engagement Team was lucky enough to attend the World Orphan Drug Congress Europe earlier in November. The virtual conference provided invaluable insights into hot topics and current issues for rare diseases. Of much interest to our team were patient centricity, initiatives working with patient groups/advocates and, specifically, discussions around access and…